title: Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer.
abstract: OBJECTIVE
  The aim of this study was to construct a prognostic index that predicts risk of relapse in women who have completed first-line treatment for ovarian cancer (OC).
  
  
  METHODS
  A database of OC cases from 2000 to 2010 was interrogated for International Federation of Gynecology and Obstetrics stage, grade and histological subtype of cancer, preoperative and posttreatment CA-125 level, presence or absence of residual disease after cytoreductive surgery and on postchemotherapy computed tomography scan, and time to progression and death. The strongest predictors of relapse were included into an algorithm, the Risk of Ovarian Cancer Relapse (ROVAR) score.
  
  
  RESULTS
  Three hundred fifty-four cases of OC were analyzed to generate the ROVAR score. Factors selected were preoperative serum CA-125, International Federation of Gynecology and Obstetrics stage and grade of cancer, and presence of residual disease at posttreatment computed tomography scan. In the validation data set, the ROVAR score had a sensitivity and specificity of 94% and 61%, respectively. The concordance index for the validation data set was 0.91 (95% confidence interval, 0.85-0.96). The score allows patient stratification into low (<0.33), intermediate (0.34-0.67), and high (>0.67) probability of relapse.
  
  
  CONCLUSIONS
  The ROVAR score stratifies patients according to their risk of relapse following first-line treatment for OC. This can broadly facilitate the appropriate tailoring of posttreatment care and support.
authors: *Imperial College Healthcare NHS Trust, Garry Weston Cancer Centre, and †Ovarian Cancer Action Research Centre, Hammersmith Hospital; and ‡Division of Experimental Medicine, Imperial College London, Hammersmith Campus, London, United Kingdom.
authors: Ivana
authors: I
authors: Rizzuto
authors: Chara
authors: C
authors: Stavraka
authors: Jayanta
authors: J
authors: Chatterjee
authors: Jane
authors: J
authors: Borley
authors: Thomas Glass
authors: TG
authors: Hopkins
authors: Hani
authors: H
authors: Gabra
authors: Sadaf
authors: S
authors: Ghaem-Maghami
authors: Les
authors: L
authors: Huson
authors: Sarah P
authors: SP
authors: Blagden
mesh_terms: D000465:Algorithms; D018394:CA-125 Antigen / Q000097:blood; D065426:Cytoreduction Surgical Procedures; D005185:Fallopian Tube Neoplasms / Q000097:blood / Q000473:pathology* / Q000601:surgery; D005260:Female; D006801:Humans; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000000981:diagnostic imaging / Q000473:pathology*; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D010051:Ovarian Neoplasms / Q000097:blood / Q000473:pathology* / Q000601:surgery; D010534:Peritoneal Neoplasms / Q000097:blood / Q000473:pathology* / Q000601:surgery; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
chemical_list: D018394:CA-125 Antigen
references: BJOG. 2009 Feb;116(3):372-80
references: 19187369
references: Br J Cancer. 2006 Nov 20;95(10):1314-20
references: 17088903
references: Gynecol Oncol. 2012 Nov;127(2):367-74
references: 22800653
references: J Ovarian Res. 2009 Oct 09;2:13
references: 19818123
references: Gynecol Oncol. 2013 Apr;129(1):97-102
references: 23290990
references: Eur J Gynaecol Oncol. 2013;34(2):148-51
references: 23781586
references: Eur J Cancer. 2012 Jul;48(10):1476-83
references: 22047635
references: Transl Oncol. 2010 Aug 01;3(4):230-8
references: 20689764
references: Lancet Oncol. 2014 Jan;15(1):23-34
references: 24314615
references: Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32
references: 24078660
references: Gynecol Oncol. 2008 Jan;108(1):191-4
references: 17950784
references: Int J Gynecol Cancer. 2012 Mar;22(3):367-71
references: 22237384
references: J Reprod Med. 1996 Mar;41(3):140-2
references: 8778409
references: Acta Obstet Gynecol Scand. 1994 Sep;73(8):658-62
references: 7941993
references: Br J Cancer. 2001 Sep 28;85(7):944-52
references: 11592763
references: Br J Cancer. 2008 Jan 15;98(1):199-205
references: 18071361
references: Gynecol Oncol. 2013 Oct;131(1):15-20
references: 23877013
references: J Clin Epidemiol. 2010 Aug;63(8):826-33
references: 20630332
references: Gynecol Oncol. 2010 Nov;119(2):259-64
references: 20800269
references: Gynecol Oncol. 2012 Apr;125(1):25-30
references: 22155261
references: Gynecol Oncol. 2011 Sep;122(3):541-7
references: 21640372
references: J Clin Oncol. 2003 Sep 1;21(17):3194-200
references: 12860964
references: Br J Cancer. 2003 Sep 15;89(6):1022-7
references: 12966419
references: Cochrane Database Syst Rev. 2013 Nov 18;(11):CD010299
references: 24249483
references: J Gynecol Oncol. 2013 Jan;24(1):37-43
references: 23346312
references: CA Cancer J Clin. 2013 Jan;63(1):11-30
references: 23335087
references: Gynecol Oncol. 2012 Jul;126(1):36-40
references: 22370601